At a glance
- Originator Allergan
- Class Antiglaucomas
- Mechanism of Action Alpha 2 adrenergic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Glaucoma
Most Recent Events
- 08 May 2020 Allergan has been acquired and merged into AbbVie
- 09 Sep 1999 No-Development-Reported for Glaucoma in USA (Ophthalmic)
- 06 Aug 1996 New profile